By Colin Kellaher
Chimerix shares surged to a multi-year high Wednesday after the biopharmaceutical company agreed to be acquired by larger peer Jazz Pharmaceuticals for about $935 million.
Jazz is paying $8.55 a share in cash for Chimerix, a 72% premium to Tuesday's closing price.
Shares of the Durham, N.C., company were recently up 70% at $8.41, reaching levels not seen since 2021.
Chimerix shares were trading as low as 75 cents last August before the stock began to rally late last year on hopes for its dordaviprone, which is under Food and Drug Administration review for accelerated approval in a rare, high-grade brain tumor.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 05, 2025 10:00 ET (15:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。